ClinicalTrials.gov
public full text
Public Domain
This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Related documents
- CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL#889283
- CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma#1032395
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas#349945
- CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL#868066
- Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma#140978
Record · ID 67863 · SHA-256 e5bfa50054351e7a
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive